Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who served as Vice President of Talent and Organizational Culture at Roche China and Head of the Chinese Market Access Hospital Key Account Management Department. Chen has decided to leave Roche to pursue external development opportunities. Since joining Roche in 2019, she has been instrumental in driving multiple transformation projects and developing Roche China’s talent strategy. She was promoted to her most recent position in 2022.
The company has undergone significant personnel and structural changes since the second half of 2023. This includes the departure of Chen Shaofeng, who was responsible for Roche China’s customer interaction business model in the field of specialty drugs, including ophthalmology, neuroscience, anti-infection, and immunology. Chen Shaofeng’s role was subsequently assumed by Chen Yijuan, who was leading the global integration strategy for Xofluza, in July 2023. In August 2023, Roche further reorganized its business sectors, splitting the primary anti-infection and neurological and rare disease treatment field into two distinct areas: neurological and rare disease treatment, and respiratory and anti-infection treatment.
According to Roche’s 2023 financial report, the company generated CHF 2.875 billion in pharmaceutical revenues in China, marking a 6% year-on-year increase and accounting for 6.4% of Roche’s global pharmaceutical revenues. – Flcube.com
